TARDBP and frontotemporal dementia: Our findings highlight the potential utility of skin TDP-43 pathology as an early, accessible biomarker for trial stratification for example in FTD, where underlying molecular subtypes such as FTD-TDP, FTD-TAU, and FTD-FUS have distinct prognostic and therapeutic implications.